Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 53.32B 7.89B 6.86B 6.39B 5.86B 11.07B 753B 11.24B 75.28B 29.55B 375B 29.64B 28.99B 1,258B P/E 2026 *
39.2x
P/E 2027 * 31.4x
Enterprise Value 48.27B 7.15B 6.21B 5.78B 5.31B 10.02B 682B 10.18B 68.15B 26.75B 340B 26.84B 26.25B 1,139B EV / Sales 2026 *
5.97x
EV / Sales 2027 * 5.04x
Free-Float
61.14%
Yield 2026 *
0.96%
Yield 2027 * 1.18%
Jul. 31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
Jul. 27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
Jun. 11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
May. 27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
May. 20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
May. 15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
May. 13 Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says RE
May. 04 JPMorgan Chase's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 7.64% on Apr 28 from 8.18%, HKEX filing shows RE
Apr. 28 Asymchem Laboratories' Profit Falls 6.8% in Q1; Shares Rise 8% MT
Apr. 27 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 27 Asymchem Laboratories (Tianjin) Q1 net profit down 6.8% Y/Y RE
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 7.54B
-0.53%-3.95%+55.23%+152.74% 1,030B
+0.21%-2.68%+55.61%+53.02% 617B
-2.51%-3.25%+32.76%+67.76% 455B
+0.06%-0.42%+37.53%+30.67% 350B
-0.14%-0.24%+34.41%+39.01% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+2.43%+30.52%+64.49% 209B
-0.82%+0.70%+15.96%+71.01% 163B
Average -1.24%+1.38%+29.58%+50.11% 401.41B
Weighted average by Cap. -1.02%-0.11%+38.70%+72.68%

Financials

2026 *2027 *
Net sales 8.08B 1.2B 1.04B 968M 889M 1.68B 114B 1.7B 11.41B 4.48B 56.85B 4.49B 4.39B 191B 9.7B 1.44B 1.25B 1.16B 1.07B 2.02B 137B 2.05B 13.7B 5.38B 68.26B 5.39B 5.28B 229B
Net income 1.4B 208M 180M 168M 154M 291M 19.81B 296M 1.98B 777M 9.86B 779M 762M 33.08B 1.77B 262M 228M 212M 194M 367M 24.98B 373M 2.5B 980M 12.44B 983M 961M 41.71B
Net Debt -5.05B -748M -650M -605M -555M -1.05B -71.36B -1.06B -7.13B -2.8B -35.53B -2.81B -2.75B -119B -4.39B -650M -565M -526M -483M -912M -62.07B -926M -6.2B -2.43B -30.9B -2.44B -2.39B -104B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Date Price Change
Trader
Investor
Global
Quality
ESG MSCI
-